Cozad Asset Management Inc. Reduces Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

by · The Cerbat Gem

Cozad Asset Management Inc. cut its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,910 shares of the company’s stock after selling 5,000 shares during the quarter. Cozad Asset Management Inc.’s holdings in AstraZeneca were worth $2,798,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Martin Investment Management LLC grew its holdings in shares of AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after buying an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC increased its holdings in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares during the period. Creative Planning raised its stake in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after purchasing an additional 16,692 shares during the last quarter. TD Asset Management Inc raised its stake in shares of AstraZeneca by 8.6% in the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after purchasing an additional 121,876 shares during the last quarter. Finally, Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca during the second quarter worth about $269,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $63.85 on Thursday. The company has a market capitalization of $197.97 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The company’s fifty day moving average price is $78.45 and its 200 day moving average price is $78.75. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AZN. TD Cowen increased their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $89.75.

Read Our Latest Stock Analysis on AstraZeneca

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories